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Summary
Adaptive enrichment designs involve preplanned rules for modifying enrollment criteria based
on accrued data in an ongoing trial. For example, enrollment of a subpopulation where there
is sufficient evidence of treatment efficacy, futility, or harm could be stopped, while enrollment
for the remaining subpopulations is continued. Most existing methods for constructing adaptive
enrichment designs are limited to situations where patient outcomes are observed soon after
enrollment. This is a major barrier to the use of such designs in practice, since for many diseases
the outcome of most clinical importance does not occur shortly after enrollment. We propose a
new class of adaptive enrichment designs for delayed endpoints. At each analysis, semiparametric,
locally efficient estimators leverage information in baseline variables and short-term outcomes to
improve precision. This can reduce the sample size required to achieve a desired power. We
propose new multiple testing procedures tailored to this problem, which we prove to strongly
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control the familywise Type I error rate, asymptotically. These methods are illustrated through
simulations of a trial for a new surgical intervention for stroke.
Key words: multiple testing procedure; treatment effect heterogeneity
1. Introduction
We address the problem of designing a confirmatory randomized trial of an experimental treat-
ment versus control when the primary outcome is measured with delay and there are multiple
subpopulations of interest. Our methods were developed to solve a problem in designing a trial
of a new surgical treatment for stroke, with outcomes measured a fixed time (180 days) from
enrollment. However, our general method can also be applied to time-to-event outcomes.
To illustrate our approach, consider an analysis that occurs just after 50% of a trial’s total
enrollment. Due to delayed outcomes, less than 50% of final (i.e., primary) outcomes are ob-
served. However, all enrolled participants have baseline variables observed, some have short-term
outcomes observed, and a further subset have the final outcome observed. If the short-term out-
comes and baseline variables are correlated with the final outcome, they can provide valuable
information that we harness through the semiparametric, locally efficient estimators of van der
Laan and Gruber (2012). In a randomized trial, these estimators converge to the true average
treatment effect, without having to make any parametric model assumptions. To the best of our
knowledge, we give the first application of such an estimator in adaptive enrichment designs with
delayed outcomes. In simulations that mimic key features of a completed stroke trial, this leads
to tangible improvements in precision and a 19-20% reduction in both expected sample size and
maximum sample size, compared to the standard, unadjusted estimator that ignores short-term
outcomes and baseline variables.
Our designs strongly control the familywise Type I error rate as required, e.g., by the U.S.
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Food and Drug Administration in their draft guidance on adaptive designs for drugs and biologics
(FDA, 2010). This means that the probability of rejecting one or more true null hypotheses is
at most the desired level, regardless of the sign and magnitude of each subpopulation treatment
effect. Two general techniques for ensuring strong control of the familywise Type I error rate
in adaptive enrichment designs are the the p-value combination approach (Bretz and others,
2006; Schmidli and others, 2006; Jennison and Turnbull, 2007; Brannath and others, 2009), and
the approach based on modified, group sequential computations (Stallard, 2011; Magnusson and
Turnbull, 2013). These approaches require assumptions that are not guaranteed to hold when
using semiparametric, locally efficient estimators in our context, as described in Section 4. To
take advantage of precision gains from these estimators, we propose a class of multiple testing
procedures that do not require these assumptions; these procedures build on ideas from the modi-
fied, group sequential computation approach. An alternative to our approach is to use conditional
error functions as in the adaptive enrichment designs of (Friede and others, 2012); however, this
involves computational challenges described in Section 7.
We present our motivating application in Section 2. The general problem is defined in Sec-
tion 3. In Section 4, we describe the semiparametric, locally efficient estimators used in our
designs. The proposed class of adaptive enrichment designs for delayed outcomes is given in Sec-
tion 5. In Section 6, we apply our designs in simulations that mimic features of the data from a
completed stroke trial. Section 7 describes extensions, limitations, and areas for future research.
2. Motivating Application: MISTIE stroke trial
We consider the problem of planning a Phase III trial to evaluate a new surgical treatment for
stroke, called Minimally-Invasive Surgery Plus rt-PA for Intracerebral Hemorrhage Evacuation,
abbreviated as MISTIE (Morgan and others, 2008). The aim is to assess whether the MISTIE
surgical treatment is superior to the standard of care. The primary outcome is a participant’s
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degree of disability as measured by the modified Rankin Scale (mRS) at 180 days from enrollment.
A mRS score of 3 or less is considered a successful outcome. Define the average effect of the
MISTIE treatment to be the difference between the probability of a successful outcome under
assignment to MISTIE (treatment) versus standard of care (control).
Prior data indicated greater uncertainty of the treatment effect for the subpopulation of
participants with large (at least 10ml) intraventricular hemorrhage (IVH) at baseline, called
large IVH participants. All others are called small IVH participants. The clinical investigators
thought two scenarios were most likely to occur if the treatment was effective at all: either the new
treatment would benefit both subpopulations, or it would benefit only small IVH participants.
We explore adaptive designs for testing the corresponding null hypotheses of no mean treatment
benefit for the overall population and for the small IVH subpopulation.
3. Problem Definition
3.1 Subpopulations, Data Structure for Each Participant, and Analysis Timing
We assume the overall population is partitioned into m disjoint subpopulations, which are pre-
planned functions of variables measured before randomization. For each s ∈ {1, . . . ,m}, let ps
denote the proportion of the overall population in subpopulation s, which we assume is known.
Each participant i has full data vector Di = (Ei, Si,Wi, Ai, L
(1)
i , . . . , L
(T )
i , Yi) when followed
up completely, where Ei is the enrollment time, Si denotes subpopulation, Wi is a vector of
baseline (pre-randomization) variables, Ai is the treatment indicator (Ai = 1 indicates treatment
and Ai = 0 indicates control), L
(1)
i , . . . , L
(T )
i are variables observed after randomization, and Yi
is the final (i.e., primary) outcome. We assume that L
(1)
i , . . . , L
(T )
i , Yi are observed at preplanned
durations (in days) d = (d1, . . . , dT , dY ), respectively, from the time of enrollment, such that
0 < d1 < · · · < dT < dY . The subscript i is omitted when referring to a generic participant.
A special case of interest is where L(1), . . . , L(T ) represent the same quantity as in the primary
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outcome, but measured at the earlier times d1, . . . , dT ; we refer to L
(1), . . . , L(T ) as short-term
outcomes, though in general they can be any variables measured after randomization. For exam-
ple, in the MISTIE trial we have T = 1 and the following data are measured for each participant:
enrollment time E, subpopulation S ∈ {1, 2} (small or large IVH, respectively); baseline variables
W = (NIH Stroke Scale, clot volume, and Glasgow Coma Scale); treatment indicator A; indicator
L(1) of functional disability score (mRS) 6 3 at 30 days from enrollment; the primary outcome
Y , which is the indicator of mRS 6 3 at 180 days from enrollment.
Let K denote the maximum number of stages and Ns,max denote the maximum, cumulative
sample size for each subpopulation s, both of which are preplanned. The maximum total sample
size is N =
∑
s6mNs,max. Define qs = Ns,max/N . At the start of the trial, all subpopulations
are continuously enrolled. Let e denote the combined population enrollment rate in participants
per day, which we assume to be a constant. We assume enrollment rates are proportional to
subpopulation sizes, i.e., if enrollment has not stopped for subpopulations s and s′, the ratio of
the cumulative number enrolled from subpopulation s and s′ is ps/ps′ . The enrollment time for
the lth participant from subpopulation s is l/(eps), for each s 6 m, l 6 Ns,max. We order the
set of all participants by increasing enrollment time (with ties broken arbitrarily), and denote
the full data vector for the ith participant in this ordering by Di as defined above. Each stage’s
duration can be any preplanned function of calendar time and/or information accrued, as defined
in Section 5. The maximum trial duration D, which is when analysis K occurs, is the time to
enroll all participants plus dY , i.e., D = maxs6m{Ns,max/(eps)}+ dY .
3.2 Assumptions, Hypotheses, Censoring, and Accrual Modification Rules
For each participant i, we assume that conditioned on Ei and Si = s, his/her baseline data
Wi is a random draw from an unknown distribution Qs(W ), independent of the data from all
previously enrolled participants. By design, each participant is randomized with probability 1/2
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to either study arm independent of (E,S,W ), i.e., P (A = 1 | E,S,W ) = 1/2; we call this
the randomization assumption. We assume that for each participant i, conditioned on Ei, Si =
s,Wi, Ai, the vector (L
(1)
i , . . . , L
(T )
i , Yi) is a random draw from distribution Q
′
s(L
(1), . . . , L(T ), Y |
A = Ai,W = Wi) independent of the data from all previously enrolled participants. Denote the
unknown distributions by Q = {(Qs, Q′s) : s 6 m}. We make no parametric model assumptions,
nor do we assume any relationships between distributions for different subpopulations. We use a
nonparametric model Q where the only assumptions are the randomization assumption and that
Q satisfies regularity conditions given in Appendix A of the Supplementary Material.
Let δs = E(Y | A = 1, S = s) − E(Y | A = 0, S = s) denote the average treatment effect
for subpopulation s ∈ {1, . . . ,m}. For each j ∈ {0, . . . , J}, let S˜j ⊆ {1, . . . ,m} denote the jth
composite population of interest, consisting of the union of subpopulations in S˜j . The overall
population will generally be of interest, and we denote it by S˜0 = {1, . . . ,m}. The average
treatment effect in population S˜j is ∆j = E(Y | A = 1, S ∈ S˜j) − E(Y | A = 0, S ∈ S˜j) =∑
s∈S˜j psδs
/∑
s∈S˜j ps. For each j ∈ {0, . . . , J}, define the null hypothesis H0j : ∆j 6 0 and
alternative hypothesis ∆j > 0. Our general problem is to construct adaptive enrichment designs
to test the set of null hypotheses {H0j : j = 0, . . . , J}. For any distribution Q ∈ Q, let T (Q)
denote the set of true null hypotheses under Q. We require at least nmin > 1 participants from
each population S˜j to have Y observed before analysis 1 takes place.
We assume L(0) = (E,S,W,A) are observed at enrollment. Let L(T+1) = Y . For each partic-
ipant i, stage k, and t 6 T + 1, let C(t)i,k denote the indicator that L
(t)
i is observed by the end
of stage k. In the special case of the MISTIE trial, for any participant i and stage k, the vector
(C
(0)
i,k , C
(1)
i,k , C
(2)
i,k ) has one of the following forms:
(0, 0, 0): no data observed, i.e., not yet enrolled by end of stage k;
(1, 0, 0): enrollment time E, subpopulation S, baseline variables W and study arm A observed;
(1, 1, 0): E, S, W , A, and short-term outcome L(1) observed;
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(1, 1, 1): complete data vector (E,S,W,A,L(1), Y ) observed.
In general, we assume a monotone missingness structure, i.e., that C
(t)
i,k > C
(t+1)
i,k for each t ∈
{0, . . . , T}, k 6 K, i 6 N , and that C(t)i,k 6 C(t)i,k+1 for each t ∈ {0, . . . , T + 1}, k 6 K − 1, i 6 N .
Define the pipeline participants at analysis k to be those enrolled with Y not yet observed.
We assume the only cause of missing data is administrative censoring due to some participants
not yet having experienced short-term and/or final outcomes at an interim analysis. In Section 7
we describe how to incorporate additional right censoring due to loss to follow-up. For clarity of
exposition, we assume throughout that variances and covariances are known; in practice, they
will be estimated as the trial progresses, e.g., using the nonparametric bootstrap as described in
Appendix D of the Supplementary Material.
An early stop of accrual (of information) for subpopulation s means that both enrollment
and continuation of follow-up are halted. Unless subpopulation s accrual is stopped early, it has
ongoing enrollment (until Ns,max is reached) and follow-up (until all Ns,max participants have Y
observed). Let rk denote the preplanned rule for accrual modification at analysis k < K. It can
be any measurable function from the data available at analysis k to the set of subpopulations for
which accrual will continue during stage k + 1, under the restrictions that accrual can only be
stopped at interim analysis times and that once a subpopulation’s accrual has been stopped it
cannot be restarted. An example is given in Section 6.3. Let r = (r1, . . . , rK−1).
3.3 Asymptotic Framework
Our asymptotic results, such as consistency and asymptotic normality of estimators, involve a
sequence of hypothetical trials with sample sizes in all stages converging to infinity. We fix the
proportions ps, the delay times d, the maximum duration D, the analysis times, and the dis-
tribution Q. We set Ns,max = qsN for fixed constants qs > 0 that sum to 1, and consider a
sequence of trials in which N goes to infinity. This implies that the enrollment rate e goes to
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infinity, the number enrolled in each stage goes to infinity, and if enrollment has not stopped
for subpopulation s by the end of stage k then the proportion of its participants in the pipeline
is a positive constant that depends on k; these results are proved in Appendix A.1 of the Sup-
plementary Material. This framework is similar to (Scharfstein and others, 1997, Section 2),
except ours is more restricted because the enrollment process and delay times are fixed. Though
our asymptotic results only require Ns,max/N to converge to qs, for clarity of exposition we
consider the case where Ns,max/N = qs. Consider any Q ∈ Q, rule r, and multiple testing
procedure M . We say M controls the familywise Type I error rate at level α∗, asymptotically,
if lim supN→∞ PQ,r,N{M rejects at least one null hypothesis in T (Q)} 6 α∗, where PQ,r,N de-
notes probability under distribution Q, rule r, and maximum sample size N . If this holds for any
Q ∈ Q, then M strongly controls the familywise Type I error rate, asymptotically. Familywise
Type I error control for fixed N is defined similarly, except dropping lim supN→∞.
3.4 Unadjusted Estimator
We define all estimators, statistics, and corresponding covariance matrices as if a rule r is used
such that no subpopulation’s accrual is ever stopped early. This poses no problem since our
testing procedures never use an estimator or statistic if any of its component subpopulations had
accrual stopped early at a prior analysis. For a given population, the unadjusted estimator of the
average treatment effect is the difference between sample means of Y comparing those assigned to
A = 1 versus A = 0. At any analysis time, only the data from participants who have Y observed
are used. For each subpopulation s ∈ {1, . . . ,m}, the unadjusted estimator of δs at analysis k is
δˆunadjs,k =
∑
i YiC
(T+1)
i,k 1 [Ai = 1, Si = s]∑
i C
(T+1)
i,k 1 [Ai = 1, Si = s]
−
∑
i YiC
(T+1)
i,k 1 [Ai = 0, Si = s]∑
i C
(T+1)
i,k 1 [Ai = 0, Si = s]
,
where 1[X] is the indicator variable taking value 1 if X is true and 0 otherwise. The unadjusted
estimator of ∆j for composite population S˜j at stage k is ∆ˆunadjj,k =
∑
s∈S˜j psδˆ
unadj
s,k
/∑
s∈S˜j ps.
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4. Semiparametric, Locally Efficient Estimators
To take advantage of prognostic information in baseline variables and short-term outcomes, we
use estimators that build on the general theory of semiparametric, locally efficiency of Robins and
Rotnitzky (1992). When baseline variables and short-term outcomes are strongly correlated with
the final outcome, as in the MISTIE trial, these estimators can have greater precision than the
unadjusted estimator. We use a targeted maximum likelihood estimator (TMLE) for longitudinal
data developed by van der Laan and Gruber (2012) and implemented in the R package ltmle
(Schwab and others, 2014). This estimator combines features of the general targeted maximum
likelihood template of van der Laan and Rubin (2006) with the sequential regression approach
of Robins (2000); Bang and Robins (2005). We call this the adjusted estimator. Let ∆ˆadjj,k denote
the adjusted estimator of ∆j based on all data from participants in population S˜j collected up
to and including stage k. The precise definition of this estimator is given in Appendix B of the
Supplementary Material. It is also possible to use the semiparametric, locally efficient estimators
of, e.g., Lu and Tsiatis (2011); Rotnitzky and others (2012); Gruber and van der Laan (2012);
Parast and others (2014); Zhang (2015), as we discuss in Section 7.
The adjusted estimator involves working models that are fit using data accrued at a given
analysis. The term “working model” means we do not assume that the true, unknown data
generating distribution Q satisfies any of the assumptions of these models. For example, our
TMLE implementation uses a logistic regression working model for P (Y = 1 | L(1), A,W, S ∈ S˜j)
for each j 6 J , but we do not assume the conditional distribution of Y given (L(1), A,W, S) has the
functional form of a logistic regression model. Under regularity conditions given in Appendix A
of the Supplementary Material, the adjusted estimator is consistent regardless of whether the
working models are correctly specified. If they are correctly specified, then the adjusted estimator
achieves the semiparameteric efficiency bound; this is the local efficiency property of the estimator.
When our discussion applies to a generic estimator, we suppress adj and unadj in the subscript.
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For a given estimator ∆ˆj,k of ∆j , define the corresponding Wald statistic Zj,k = ∆ˆj,k/Var(∆ˆj,k)
1/2,
where Var denotes variance. When the adjusted estimator involves at least a few baseline vari-
ables or short-term outcomes that are continuous-valued (or discrete-valued with many levels and
treated as continuous in working models), e.g., as in the MISTIE example, then we expect these
models to be at least somewhat misspecified. We consider such a situation throughout the paper.
For a given S˜j , the statistics Zj,1, . . . , Zj,K for the adjusted estimator are not guaranteed to
have the canonical covariance that arises when estimators (rescaled by the information) have
the independent increments property described by Scharfstein and others (1997); Jennison and
Turnbull (1999). This was shown for estimators based on generalized estimating equations by
Shoben and Emerson (2014). We show this occurs for the TMLE and some other locally efficient
estimators when working models are misspecified, in Appendix A of the Supplementary Material.
We furthermore show this occurs even when baseline variables but no short-term outcomes are
used in working models. The upshot is that the general techniques for ensuring familywise Type
I error control listed in Section 1 cannot be directly applied, since they assume the canonical
covariance or more generally the so-called p-clud property, neither of which is guaranteed to hold
for the adjusted estimator. An exception involving only linear models is described in Appendix A.
5. Multiple Testing Procedure using Interleaved Error Spending Functions
Error-spending functions were introduced by Slud and Wei (1982); Lan and DeMets (1983) for
a single population, but have not been applied in the manner we describe below for multiple
populations in adaptive enrichment designs with delayed outcomes. Error-spending functions
set boundaries for early stopping based on the information accrued. We define a separate error
spending function for each composite population S˜j . Tests are interleaved in a way that takes
advantage of correlations among related statistics, including statistics for the same population
at different analysis times, and statistics for different but overlapping populations. We focus
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on efficacy boundaries, whose corresponding error spending functions are called alpha spending
functions. A special case of our general class of designs was given by Rosenblum and others
(2015), who only considered immediately observed outcomes, unadjusted estimators, and more
restricted designs than the class below.
For each null hypothesis H0j , at each analysis k, let Ij,k = 1/Var(∆ˆj,k) denote the accrued in-
formation corresponding to the estimator ∆ˆj,k. Define the information fraction τj,k = Ij,k/Ij,max,
where Ij,max is a predefined maximum information level for population S˜j , and Ij,0 = 0 for all
j. Let α∗ denote the desired upper bound on the familywise Type I error rate, e.g., α∗ = 0.025
(since we use one-sided tests). Define error spending functions αj : [0,∞) → [0, α∗] for each
j ∈ {0, . . . , J} that are nondecreasing, take the value 0 at τ = 0, and satisfy ∑Jj=0 αj(τ) 6 α∗
for all τ > 0. Define pij,k = max{0, αj(τj,k)− αj(τj,k−1)} and let pi = {pij,k}j6J,k6K .
Consider any accrual modification rule r, nonnegative increments pi, and Q ∈ Q. We first give
results for an arbitrary vector of statistics Z˜ = {Z˜j,k}j6J,k6K with covariance matrix Σ˜ having 1’s
on the main diagonal, and then apply these results for Z˜ equal to the Wald statistics correspond-
ing to the unadjusted or adjusted estimator. For each k define the following set of null hypotheses:
Bk(r) = {H0j : for each s ∈ S˜j , subpopulation s accrual not stopped early prior to analysis k}.
Define the ordering (k′, j′) ≺ (k, j) to mean that k′ < k or (k′ = k and j′ < j). Denote the mul-
tivariate normal distribution with mean µ and covariance matrix Σ by N(µ,Σ). The following
procedure takes as input the statistics Z˜, their covariance Σ˜, the rule r, and increments pi:
Multiple Testing Procedure M(Z˜, Σ˜, r,pi): Define Z′ = {Z ′j,k}j6J,k6K to be a random vector
with distribution N(0, Σ˜). At each analysis k 6 K, for each population S˜j , j = 0, . . . , J in turn:
1. Define uj,k to be the solution to:
P
{
Z ′j′,k′ 6 uj′,k′ for all (k′, j′) ≺ (k, j); and Z ′j,k > uj,k
}
= pij,k. (5.1)
2. RejectH0j if all of the following hold: it hasn’t already been rejected, j ∈ Bk(r), and Z˜j,k > uj,k.
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The left side of (5.1) can be computed using the multivariate normal distribution function,
e.g., implemented in the mvtnorm R package of Genz and others (2014), which takes as input
Σ˜. Given the previously computed values {uj′,k′ : (k′, j′) ≺ (k, j)}, the solution uj,k to (5.1) can
be computed to high precision by the bisection (binary search) method. In the special case that
pij,k = 0, we set uj,k = ∞. The null hypotheses rejected at the end of the trial are those that
were rejected at any stage.
Let T = T (Q) as defined on page 6. For any vector Z˜ = {Z˜j,k}j6J,k6K , define the subvector
Z˜T = {Z˜j,k : k 6 K, j : H0j ∈ T } and let Σ˜T denote its covariance matrix. For any random
vectors U,U′ taking values in Rv, we say U′ is stochastically smaller than U if for any u ∈ Rv,
P (for some v′ 6 v, U ′v′ > uv′) 6 P (for some v′ 6 v, Uv′ > uv′). A sequence U(1),U(2), . . .
taking values in Rv is asymptotically, stochastically smaller than U if for any u ∈ Rv, we have
lim supl>0 P (for some v
′ 6 v, U (l)v′ > uv′) 6 P (for some v′ 6 v, Uv′ > uv′).
Consider any Q ∈ Q, accrual modification rule r, and nonnegative increments pi that sum to
at most α∗. In Appendix C of the Supplementary Material we prove:
Theorem 5.1 Consider any vector of statistics Z˜ = {Z˜j,k}j6J,k6K with covariance matrix Σ˜
having 1’s on the main diagonal. If Z˜T is stochastically smaller than N(0, Σ˜T ), then the procedure
M(Z˜, Σ˜, r,pi) controls the familywise Type I error rate at level α∗.
Theorem 5.2 Consider any sequence Z˜(N) with corresponding covariance matrices Σ˜(N) such
that Σ˜
(N)
T converges to a limit Σ˜
∗
T with 1’s on the main diagonal, and Z˜
(N)
T is asymptotically,
stochastically smaller than N(0, Σ˜∗T ). Then M(Z˜
(N), Σ˜(N), r,pi) controls the familywise Type I
error rate, asymptotically, at level α∗.
Consider a sequence of trials with maximum sample size N going to infinity, as described in
Section 3.3. For each N , let ∆ˆ
(N)
j,k denote the unadjusted or adjusted estimator for population
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S˜j at stage k, with corresponding information I(N)j,k and Wald statistic Z(N)j,k . Similar to Scharf-
stein and others (1997, Section 3), we assume that for each j 6 J, k 6 K, limN→∞ I(N)j,k /N =
limN→∞{NVar(∆ˆ(N)j,k )}−1 = I∗j,k where I∗j,k is defined in Appendix A of the Supplementary Mate-
rial. This implies the covariance matrix Σ(N) of Z(N) converges to Σ∗ (defined in that Appendix)
with 1’s on the main diagonal. Under the regularity conditions in that Appendix, the centered
Wald statistics {(∆ˆ(N)j,k − ∆j)/Var(∆ˆ(N)j,k )1/2}j6J,k6K converge in distribution to N(0,Σ∗). For
each true H0j , we have Z
(N)
j,k = ∆ˆ
(N)
j,k /Var(∆ˆ
(N)
j,k )
1/2 6 (∆ˆ(N)j,k −∆j)/Var(∆ˆ(N)j,k )1/2, and so Z(N)T is
asymptotically, stochastically smaller than N(0,Σ∗T ). Theorem 5.2 implies M(Z
(N),Σ(N), r,pi)
controls the familywise Type I error rate, asymptotically, at level α∗. Since this holds for any
Q ∈ Q, the procedure strongly controls the familywise Type I error rate, asymptotically.
Magnusson and Turnbull (2013) present multiple testing procedures that use error spending
functions in adaptive enrichment designs. Their method is not applicable in our context since
it assumes the canonical covariance described above. It also assumes that the treatment effect
cannot be negative in any subpopulation. Negative treatment effects cannot be ruled out in the
MISTIE trial context, since it is possible that the new surgical procedure may cause damage.
6. Simulations
6.1 Overview and Design Goals
Consider the problem of planning the Phase III MISTIE trial, as introduced in Section 2. The
variables (S,W,A,L(1), Y ) defined in the third paragraph of Section 3 are measured for each
participant. We refer to those with small IVH as subpopulation 1, and those with large IVH as
subpopulation 2. The composite populations of interest are the combined population denoted by
S˜0 = {1, 2}, and subpopulation 1 denoted by S˜1 = {1}. We test the corresponding null hypotheses
H00 and H01 using Wald statistics Z0,k and Z1,k for each k 6 K in multiple testing procedure
M . We use statistics Z2,k, which involve only subpopulation 2, in the accrual modification rule
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r defined in Section 6.3. In the adaptive enrichment design literature, it is not uncommon to
consider the null hypotheses for a single subpopulation and the combined population, e.g., Wang
and others (2007); Brannath and others (2009); Jenkins and others (2011); Freidlin and others
(2013); Stallard and others (2014, Section 5). We assume p1 = 1/3 based on prior studies (Hanley,
2012). We assume the enrollment rate is 50 patients per year for subpopulation 1, and 100 per
year for subpopulation 2, based on the projected enrollment rates for the MISTIE Phase III trial.
The clinical investigators in the MISTIE trial were interested in the following three scenarios:
(a) δ1 = 12.2%, δ2 = 12.2%; (b) δ1 = 12.2%, δ2 = 0%; (c) δ1 = δ2 = 0. The values of δ1, δ2 in
scenario (a) are based on the point estimate of the average treatment effect from the MISTIE II
trial. We had the following goals: (i) 80% power to reject H00 in scenario (a); (ii) 80% power to
reject H01 in scenario (b); (iii) strong control of familywise Type I error rate at level α
∗ = 0.025.
Similar goals were also considered by Rosenblum and others (2015) in the context of immediately
observed outcomes and no baseline variables W .
6.2 Data Generating Distributions used in Simulation Study
To make our simulations realistic, we mimic features in the data from the completed MISTIE
II trial introduced in Section 2. A simple approach would be to construct simulated trials by
resampling with replacement from the MISTIE II data, so that the data generating distribution
is the corresponding empirical distribution. Unfortunately, the resampling distribution does not
satisfy the randomization assumption from Section 3.2, since there are slight correlations between
baseline variables and treatment assignment in the actual MISTIE II data set (as would generally
be expected in any given dataset). Furthermore, since no two participants in this data have
identical values of the baseline variables W , the treatment A is a deterministic function of W .
We construct data generating distributions that mimic key features of the MISTIE II data,
while satisfying the randomization assumption. Specifically, we construct distributions with sim-
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ilar correlations among W,L(1), Y as the Phase II trial data. This is achieved by adding, for each
participant from the MISTIE II data, a “twin” participant with identical baseline variables but
opposite treatment assignment, and whose L(1) and Y are generated using regression models fit
to the original data, with perturbations to the outcomes Y depending on the desired treatment ef-
fect in each subpopulation. For each scenario (a)-(c), a distribution was constructed that satisfies
the assumptions from Section 3.2, as described in Appendix E of the Supplementary Material.
6.3 Specific Adaptive Enrichment Design Used
We define our adaptive enrichment design by first giving the multiple testing procedure and
accrual modification rule r, and then presenting the analysis timing and error spending functions.
We use the multiple testing procedure M from Section 5, which generates efficacy boundaries
uj,k at each analysis k. The accrual modification rule r involves futility boundaries lj,k defined
below. The following encodes our accrual modification rule (and indicates when null hypotheses
are rejected, based on multiple testing procedure M) at the analysis at the end of stage k 6 K:
1. if Z0,k > u0,k or Z1,k > u1,k, reject the corresponding null hypotheses and stop all accrual;
2. else, if Z1,k 6 l1,k or k = K, then stop all accrual and fail to reject both null hypotheses;
3. else, if accrual continued for both subpopulations in stage k and Z2,k 6 l2,k, stop subpop-
ulation 2 accrual (and fail to reject H00) but continue subpopulation 1 in stage k + 1;
4. else, if k < K accrual continues for the same subpopulations in stage k + 1 as in stage k.
Since the above design uses multiple testing procedure M , under the conditions in Theorem 5.2
it strongly controls the familywise Type I error rate at level α∗, asymptotically. In step 1, if
both Z0,k > u0,k and Z1,k > u1,k, then H00 and H01 are rejected; if only one of these conditions
holds, then only the corresponding null hypothesis is rejected. Step 2 is motivated by the clinical
investigator’s judgment that if the treatment benefits any subpopulation, it will very likely benefit
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subpopulation 1, so the entire trial should stop for futility if Z1,k 6 l1,k. The above design (steps
1-4) is just one possible choice; the general multiple testing procedure M can be applied for any
accrual modification rule r.
We set the maximum number of stages K = 5. Alpha spending functions are from the ρ-family
of Kim and DeMets (1987) at ρ = 2, i.e., αj(τ) = cj min{τ2, 1} for each population S˜j : j ∈ {0, 1},
for nonnegative coefficients c0, c1 that sum to α
∗ = 0.025. Each analysis k 6 K occurs when the
accrued information for subpopulation 1 approximately reaches τ1,kI1,max; our approximation to
this information-based monitoring plan is described below.
First, consider the unadjusted estimator. The values of cj , Ij,max, τ1,k, lj,k for each j ∈
{0, 1}, k 6 K were chosen by searching over a set of candidate values to find those that minimize
the average of the expected sample size over scenarios (a)-(c), under the constraint that goals
(i)-(iii) are satisfied. We used the optimization procedure from Rosenblum and others (2015)
to conduct this search, which resulted in c0 = 0.003, c1 = 0.022, I0,max = 1115, I1,max = 795,
(τ1,1, τ1,2, τ1,3, τ1,4, τ1,5) = (0.16, 0.32, 0.47, 0.74, 1) and lj,k as given in Table 2. The futility bound-
aries lj,k equal 0 in most cases, with the notable exception l2,3 = ∞; this causes subpopulation
2 accrual to stop at or before analysis 3; intuitively, this is because at analysis 3, sufficient
information has accrued to achieve goal (i), so further enrollment of subpopulation 2 would be
counterproductive. The first three analysis times, when expressed in terms of information accrued
for the combined population, approximately equal (1/3, 2/3, 1)I0,max.
Next, consider the adjusted estimator. We slightly increased I0,max and decreased I1,max so
that goals (i)-(iii) are achieved using this estimator, which has a different covariance matrix than
the unadjusted estimator. Consider scenario (a). Table 1 shows the per-stage information levels
Ij,k for each estimator and Table 2 shows the corresponding sample sizes. Because information
accrues more quickly when using the adjusted estimator, its corresponding sample sizes at each
stage are smaller than those for the unadjusted estimator. The maximum sample sizes for sub-
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populations 1 and 2 when using the adjusted estimator are N1,max = 512, N2,max = 504, while
those for the unadjusted estimator are N1,max = 648, N2,max = 624.
For a given estimator, the per-stage sample sizes corresponding to the information levels in
Table 1 were almost identical across scenarios (a)-(c). For simplicity, in our simulation study we
set interim analyses to occur at the sample sizes in Table 2 (rather than at preset information
levels), for each scenario. This approximation to information-based monitoring led to negligible
differences in information accrued at each analysis, among the different scenarios. We emphasize
that the per-stage sample sizes differ by estimator, but not by scenario.
In order to assess whether the adjusted estimator performs worse than the unadjusted esti-
mator when covariates are pure noise, we consider a modified data generating distribution with
(W,L(1)) exogenous, i.e., independent of all other variables. Denote the TMLE under this type of
data generating distribution by TMLE prog∅, and denote the TMLE using the data generating
distributions in Section 6.2 (where W and L(1) are prognostic) by TMLE progW,L. We set the
analysis timing for TMLE prog∅ to be the same as for the unadjusted estimator, in calendar time.
The efficacy boundaries uj,k, which are determined by (5.1), depend on the covariance matrix
Σ of the statistics under consideration. To ease the computational burden in our simulations, we
precomputed an approximation to Σ using Monte Carlo simulation as described in Appendix D of
the Supplementary Material, and treated Σ as known. This was done separately for each estimator
and scenario (a)-(c). The resulting boundaries uj,k for scenario (a) and the unadjusted estimator
are given in Table 3. These boundaries were quite similar for each estimator and scenario (a)-(c);
the maximum absolute difference was 0.02.
Wang and others (2009) define adaptive enrichment to be a preplanned rule for restricting
enrollment based on accrued data. The above adaptive design has such a rule for early stopping of
only subpopulation 2 for futility if Z2,k 6 l2,k at analysis k = 1 or k = 2. We call this the adaptive
enrichment feature. Though the above design always stops subpopulation 2 enrollment at the end
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of stage 3, we do not consider this to be adaptive enrichment since this occurs regardless of the
accrued data. To show the value added by the adaptive enrichment feature, consider the same
design as described above except setting l2,1 = l2,2 = −∞, which disables this feature. We call
this the non-adaptive design, which we compare to the adaptive design.
6.4 Results: Power, Expected Sample Size, and Maximum Sample Size
Based on 50,000 simulated trials for each estimator and scenario (a)-(c), we computed the empiri-
cal Type I error, power, and expected sample size (ESS, defined as the expected number enrolled,
which includes those in the pipeline). These were computed under the accrual modification rule
r from Section 6.3. An exception is that when computing the familywise Type I error rate we
assumed no early stopping of accrual, in order to show that Type I error is controlled even in
this case; early stopping would only leave unchanged or decrease the Type I error.
The top half of Table 4 summarizes results for the adaptive enrichment design from Section 6.3.
In each scenario, the power of the different estimators is very similar due to the information-based
design using similar Ij,max values for each estimator. Essentially all the gains from adjusting for
prognostic variables get channeled into reducing the expected sample size. Using the adjusted
estimator (TMLE progW,L) instead of the unadjusted estimator leads to a reduction in expected
sample size of 20% in scenario (a), 19% in scenario (b), and 19% in scenario (c). Also, the
maximum sample size is 1016 for the design using the adjusted estimator (TMLE progW,L),
which is 20% less than the maximum sample size of 1272 for the unadjusted estimator. In scenario
(c), the familywise Type I error rate (assuming no early stopping of accrual) is 0.025 for each
estimator, as desired. Comparing the unadjusted estimator versus TMLE prog∅ shows that when
W and L provide no prognostic information, the adjusted estimator is almost identical to the
unadjusted estimator in power and expected sample size.
Figure 1 gives the power of each estimator at each stage. Plots (i) and (iv) of Figure 1
http://biostats.bepress.com/jhubiostat/paper275
Adaptive Enrichment Designs with Delayed Endpoints, using Locally Efficient Estimators 19
display power to reject at least H00 under scenario (a), and power to reject at least H01 under
scenario (b), respectively. These plots demonstrate that goals (i) and (ii) from Section 6.1 are
approximately achieved by all estimators. Plots (ii) and (iii) show that for each estimator, there
is low power to reject at least H00 when only subpopulation 1 benefits, and to reject at least
H01 when both subpopulations benefit. This behavior may be regarded as advantageous since
it is ideal to reject only H00 in scenario (a) and only H01 in scenario (b), these corresponding
precisely to the populations who benefit in each scenario, respectively.
The performance of the non-adaptive design defined in the last paragraph of Section 6.3 is
shown in the bottom half of Table 4. The main difference between this design and the adaptive
design from Section 6.3 is that the former has substantially larger expected sample size in sce-
narios (b) and (c). This is not surprising, since it is in these scenarios when futility stopping of
subpopulation 2 is especially useful. The two designs have similar power and Type I error rate in
all three scenarios, and similar expected sample sizes in scenario (a).
In Appendix F of the Supplementary Material, we compare the bias, variance, and mean
squared error for the unadjusted versus adjusted estimators, and the adaptive versus non-adaptive
designs. In each scenario (a)-(c), differences in the bias, variance, and mean squared error were
negligible when comparing estimators or when comparing designs.
7. Discussion
Alternative methods exist for covariate adjustment in our longitudinal setting, e.g., the estimators
of Lu and Tsiatis (2011); Rotnitzky and others (2012); Gruber and van der Laan (2012). These
estimators have enhanced efficiency properties, but to the best of our knowledge there is not
currently an R package implementing any of these methods that incorporates both baseline
variables and short-term outcomes. The multiple testing procedure in Section 5 can also be
applied for survival times, e.g., by using Wald statistics based on a modified TMLE or the
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estimators of Lu and Tsiatis (2011); Parast and others (2014); Zhang (2015).
We assumed that the only cause of missing data was administrative censoring due to some
participants not yet having their final outcomes observed. In Appendix B of the Supplementary
Material, we describe how to incorporate additional right censoring due to loss to follow-up, under
the missing at random assumption (van der Laan and Gruber, 2012).
Since the unadjusted estimator does not use information from pipeline participants, it has
the independent increments covariance structure. In our simulation study, the covariance matri-
ces and resulting boundaries uj,k from procedure M were quite similar for the unadjusted and
adjusted estimators. We conjecture that the similarity was due to a relatively low proportion
of pipeline participants at each interim analysis, and that there can be greater deviations from
the independent increments covariance structure when there are larger proportions of pipeline
participants, stronger correlations between Y and (W,L(1), . . . , L(T )), and more severe model
misspecification. Before a trial starts, it may be difficult to predict how much the covariance
matrix will deviate from the independent increments structure; therefore, it may be useful to
have a general approach as here that strongly controls the familywise Type I error rate regardless
of how large this deviation is.
The specific design in Section 6.3 stops all accrual at the first rejected null hypothesis, since
this suffices to achieve the power goals (i)-(ii) from Section 6.1. However, it is possible that alter-
native designs, which involve rules for continuing accrual after a null hypothesis is rejected, may
improve performance; this is an area of future research. The general multiple testing procedure
M in Section 5 does not require stopping the trial at the first analysis where a null hypothesis
is rejected, and can be used with any accrual modification rule r. It may be possible to real-
locate pij,k from null hypotheses that are rejected to other null hypotheses using the graphical
approaches of Bretz and others (2011); this is an area of future work.
Our simulations involved two subpopulations. The general framework in Section 5 can be
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applied to any number of subpopulations and composite populations. However, as the number
of such populations increases, so will the required sample size to achieve high power for each
population while controlling the familywise Type I error rate. It is an open problem to determine
how many populations can be accommodated before sample size becomes prohibitively large.
The conditional error function approach has been applied to two-stage, adaptive enrichment
designs by Friede and others (2012). They note that the required computations become more
demanding for designs with more than two stages. In our context, one would need to compute
conditional probabilities for a multivariate normal random vector. This is possible but more
challenging than computing the (unconditional) multivariate normal distribution function, which
can be done using the sophisticated algorithms of Genz and others (2014). However, the condi-
tional error function approach has more flexibility in how the testing procedure can be modified,
compared to our approach.
8. Supplementary Material
The Supplementary material includes the following: asymptotic results for the adjusted estimator;
the TMLE implementation; the proofs of Theorems 5.1 and 5.2; details of the data generating
distributions from Section 6; a bootstrap procedure to estimate Σ; R code for our simulations.
It is available here:
http://people.csail.mit.edu/mrosenblum/papers/SuppMatAdaptWithDelay.pdf
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Table 1: Cumulative information at each analysis for subpopulation 1, subpop-
ulation 2, and the combined population, in scenario (a).
adjusted estimator unadjusted estimator
Analysis (k) 1 2 3 4 5 1 2 3 4 5
Subpop. 1 (I1,k) 124 250 370 558 749 126 251 376 590 795
Subpop. 2 (I2,k) 256 524 763 249 487 739
Comb. Pop. (I0,k) 389 785 1140 372 740 1115
Table 2: Cumulative sample size (Cum.S.S.) at each analysis, which has the
format: number of participants with Y observed (+ number in pipeline).
Analysis (k) 1 2 3 4 5
Unadjusted estimator
Cum.S.S. Subpop. 1 104 (+24) 208 (+24) 312 (+24) 480 (+24) 648 (+0)
Cum.S.S. Subpop. 2 208 (+49) 416 (+49) 624 (+0) 624 (+0) 624 (+0)
Cum.S.S. Comb. Pop. 312 (+73) 624 (+73) 936 (+24) 1104 (+24) 1272 (+0)
Adjusted estimator
Cum.S.S. Subpop. 1 84 (+24) 168 (+24) 252 (+24) 382 (+24) 512 (+0)
Cum.S.S. Subpop. 2 168 (+49) 336 (+49) 504 (+0) 504 (+0) 504 (+0)
Cum.S.S. Comb. Pop. 252 (+73) 504 (+73) 756 (+24) 886 (+24) 1016 (+0)
Futility Boundary (l1,k) 0 0 0 0 -
Futility Boundary (l2,k) 0 0 ∞ - -
Table 3: Efficacy boundaries for scenario (a) and unadjusted estimator. H00 is
no longer tested after analysis 3.
Analysis (k) 1 2 3 4 5
H00 Efficacy Boundary (u0,k) 3.41 3.06 2.84 - -
H01 Efficacy Boundary (u1,k) 3.27 2.89 2.66 2.33 2.14
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Table 4: Power and expected sample size (ESS) for adaptive and non-adaptive
designs. Power under scenario (a) is the probability of rejecting at least H00;
power under scenario (b) is the probability of rejecting at least H01.
Adaptive Design
Scenario (a) Scenario (b) Scenario (c)
power H00 ESS power H01 ESS Type I error ESS
Estimator:
unadjusted 0.79 712 0.82 795 0.025 640
TMLE progW,L 0.81 568 0.82 643 0.025 521
TMLE prog∅ 0.79 711 0.82 794 0.025 638
Non-Adaptive Design
Scenario (a) Scenario (b) Scenario (c)
power H00 ESS power H01 ESS Type I error ESS
Estimator:
unadjusted 0.80 718 0.82 958 0.025 729
TMLE progW,L 0.82 575 0.82 771 0.025 591
TMLE prog∅ 0.80 718 0.81 959 0.025 727
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Fig. 1: Stagewise and overall power comparing estimators. Top and bottom rows
correspond to scenarios (a) and (b), respectively. Left and right columns repre-
sent power to reject at least H00 and to reject at least H01, respectively. Black bar
represents TMLE progW,L; yellow bar represents TMLE prog∅ (denoted “prog
None” in legends); white bar represents unadjusted estimator.
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